Phoremost
- Biotech or pharma, therapeutic R&D
PhoreMost is a next-generation targeted protein degradation (TPD) company, developing a pipeline of first-in-class and best-in-class degrader therapeutics within oncology and inflammation.
PhoreMost is applying its proprietary SITESEEKER® and GlueSEEKER® technologies to discover and develop novel monovalent and heterobifunctional degrader therapeutics.
We are committed to:
- unlocking the potential of novel E3 ligases to overcome some of the challenges associated with cereblon-based degraders and leverage disease-specific and tissue-specific mechanisms of action
- rationalizing the discovery and design of molecular glue degraders to greatly expand the addressable target space
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}